An Improved Version Of Egrifta An HGH Analog Has Been Approved By The FDA

Human Growth Hormone

Growth hormone is an essential hormone produced by the pituitary gland. In normal people, the production is highest during infancy and childhood with occasional boosts in the production of growth hormone associated with growth spurts. Growth hormone stimulates lipolysis and protein synthesis. Until a few years ago, growth hormones could only be manufactured by directly obtaining it from the pituitary gland. There are many supplements available on the market which claims to boost the production of growth hormones.

What is it used for?

Egrifta

Egrifta

Growth hormones are approved for HGH deficiency and emaciation seen in HIV or immunocompromised patients. However, until now no forms of HGH had been approved by the FDA for use in HIV patients. HIV patients have abnormal fat distribution with excessive fat deposition in the abdominal region, a condition known as excess abdominal visceral adipose tissue (VAT).

EGRIFTA: HGH releasing factor Analog

The Food and Drug Administration in the United States has recently approved EGRIFTA® (tesamorelin for injection) for use in HIV-infected patients with lipodystrophy. Lipodystrophy is a condition in which the body develops resistance to insulin, diabetes and fatty liver. EGRIFTA is an analog of growth hormone releasing factor and is currently the only FDA-approved therapy for HIV patients. The FDA has approved it to be used as a drug to reduce the excess abdominal fat in HIV infected patients.

EGRIFTA comes in a novel single-vial formation and is four times more potent than the currently available formulation of EGRIFTA in the market. The current formulation requires 2.0 ml of injection, however, the single vial formulation requires only 0.35 ml of injection. In addition, the new formula is stable at room temperature and doesn’t require special storage to distribute it to the patients.

“At this stage of the product’s lifecycle, the new formulation represents a tremendous opportunity to revitalize the brand. The launch of the new formulation will help to re-energize this important product for Theratechnologies and help patients manage a serious HIV co-morbidity,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

“The new formulation offers several advantages over the currently marketed two-vial formulation. This will definitely help to support growth in the coming months and years,” added Mr. Tanguay.

EGRIFTA®

EGRIFTA® is currently approved in the United States, Canada, and Mexico.

Contraindications to take EGRIFTA®

• Pituitary gland disorders
Cancer/ undergoing cancer therapy
• Allergic to tesamorelin
• Pregnant women
• Children less than 18 years of age.

The most common side effects of EGRIFTA® :

1. Joint pain
2. Pain in legs and arms
3. Swelling in your legs
4. Muscle pain
5. Tingling, numbness, and pricking
6. Nausea and vomiting

Related Article:

 

Leave a Reply

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.